Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib.

Abstract excerpt

PURPOSE: The p.G12C mutation in KRAS is commonly found in many cancers and was previously untreatable until drugs like sotorasib were developed. However, up to 15% of patients treated with sotorasib have experienced hepatobiliary adverse events. To investigate whether these side effects are more common among sotorasib users, a pharmacovigilance study is necessary. METHODS: This study used the FDA adverse event...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Chemical and Drug Induced Liver Injury
• Share to Databases, Factual